GlassScriptPhysician profile
Kathy M Dietlin
NPI 1699734756
$14,133.64
in general payments reported to CMS, 2019-2025
31 companies · $21.45 in 2025
The $21.45 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,118 · 2020: $2,069 · 2021: $2,405 · 2022: $3,192 · 2023: $3,345 · 2024: $984 · 2025: $21.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.45 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,243.56 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,663.06 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,097.17 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,043.31 | 2019-2024 | Dupixent |
| Csl Behring | $733.50 | 2019-2023 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $686.62 | 2020-2024 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $626.49 | 2019-2025 | |
| Genentech USA, INC. | $523.83 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.83 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Pharming Healthcare, INC. | $425.54 | 2019-2023 | Ruconest |
| Pfizer INC. | $385.30 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $293.01 | 2020-2022 | |
| Kaleo, INC. | $282.89 | 2019-2022 | |
| Abbvie INC. | $272.26 | 2022-2023 | Rinvoq |
| Biocryst US Sales Co., LLC | $216.92 | 2021-2024 | Orladeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $176.50 | 2022-2023 | Adbry |
| Aimmune Therapeutics, INC. | $157.16 | 2020-2022 | |
| Shire North American Group INC | $141.21 | 2019 | |
| Amgen INC. | $138.04 | 2021-2023 | Tezspire |
| Covis Pharma Gmbh | $126.58 | 2021-2022 | |
| Optinose US, INC. | $105.02 | 2019-2024 | |
| Octapharma USA, INC. | $63.58 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $63.47 | 2021 | |
| Alk-Abello, INC | $43.98 | 2019 | |
| Incyte Corporation | $42.78 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $35.18 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $32.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.88 | 2022 | |
| Merck Sharp & Dohme LLC | $15.62 | 2021 | |
| Hikma Pharmaceuticals USA | $14.05 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Dietlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.